News All of Ferrer’s information, just a click away Home News normal Apply We’ve been awarded EcoVadis GOLD Rating! . Thu, 03/30/2023 - 09:29 Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor to treat Progressive Supranuclear Palsy (PSP) . Wed, 02/22/2023 - 09:30 We achieve Great Place To Work certification in 5 countries . Tue, 11/29/2022 - 18:17 More than 500 people from Ferrer participate in positive impact activities in nine countries on the Days for Good . Fri, 10/07/2022 - 10:02 The polypill reduces cardiovascular mortality by 33% in patients treated after myocardial infarction . Thu, 08/25/2022 - 11:55 We invested more than 60% of our net profits in social and environmental causes . Thu, 07/28/2022 - 13:56 We bring ALSton the dragon to life to raise awareness of ALS . Tue, 06/21/2022 - 09:53 We celebrate our first Family & Friends Day . Fri, 06/17/2022 - 09:46 We consolidate our commitment to flexible working . Wed, 06/15/2022 - 07:33 Ferrer participates in B Lab Spain's B Good Day . Fri, 05/27/2022 - 09:19 Cargar más For requests for interviews or information, please contact the Communications Department CONTACT US alternatively, please dial +34 936 003 779 See more R&D Strategy Business Development
Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor to treat Progressive Supranuclear Palsy (PSP) . Wed, 02/22/2023 - 09:30
More than 500 people from Ferrer participate in positive impact activities in nine countries on the Days for Good . Fri, 10/07/2022 - 10:02
The polypill reduces cardiovascular mortality by 33% in patients treated after myocardial infarction . Thu, 08/25/2022 - 11:55
We invested more than 60% of our net profits in social and environmental causes . Thu, 07/28/2022 - 13:56